Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
Axogen, Inc. Announces New Leadership Appointments
Axogen, Inc. Reports Second Quarter 2024 Financial Results
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix(TM)
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.